An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00936741 |
Recruitment Status :
Completed
First Posted : July 10, 2009
Results First Posted : April 2, 2014
Last Update Posted : April 2, 2014
|
Sponsor:
Corcept Therapeutics
Information provided by (Responsible Party):
Corcept Therapeutics
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Tracking Information | ||||
---|---|---|---|---|
First Submitted Date ICMJE | July 9, 2009 | |||
First Posted Date ICMJE | July 10, 2009 | |||
Results First Submitted Date ICMJE | September 18, 2013 | |||
Results First Posted Date ICMJE | April 2, 2014 | |||
Last Update Posted Date | April 2, 2014 | |||
Study Start Date ICMJE | July 2009 | |||
Actual Primary Completion Date | September 2012 (Final data collection date for primary outcome measure) | |||
Current Primary Outcome Measures ICMJE |
Number of Participants With Adverse Events [ Time Frame: Up to three years. ] Subjects who received at least one dose of mifepristone were included in the safety analysis.
|
|||
Original Primary Outcome Measures ICMJE |
Long term safety of mifepristone treatment [ Time Frame: 12 months ] | |||
Change History | ||||
Current Secondary Outcome Measures ICMJE |
The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity [ Time Frame: Up to three years. ] The mean Investigator's rating of the change in subject's signs and symptoms of Cushing's syndrome from Baseline (Entry into C1073-415) to Endpoint on the Physician's Global Assessment of Disease Severity was ranked on a 9-point scale (9 = much worse, 7 = worse, 5 = no change, 3 = better, 1 = much better). Higher scores indicate more severe illness. Scoring was done at all visits except the 6 Week Follow-up visit; the final visit result (Endpoint) is reported here.
The instruction was "Rate the change in the subject's signs and symptoms of Cushing's from Baseline (1 = much better to 9 = much worse)".
|
|||
Original Secondary Outcome Measures ICMJE |
Persistence of therapeutic benefit due to continued mifepristone treatment [ Time Frame: 12 months ] | |||
Current Other Pre-specified Outcome Measures | Not Provided | |||
Original Other Pre-specified Outcome Measures | Not Provided | |||
Descriptive Information | ||||
Brief Title ICMJE | An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome | |||
Official Title ICMJE | An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome | |||
Brief Summary | Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator. | |||
Detailed Description | Up to 50 subjects will receive mifepristone daily. Subjects completing 24 weeks of mifepristone treatment under Corcept protocol C1073-400 (NCT00569582) will be eligible to continue treatment for an additional 1 year. Assessments of safety, as evaluated by physical examinations, vital signs, laboratory tests and adverse events, will be made. Persistence of improvement in response to mifepristone treatment will also be evaluated during this extension study by assessing the continued or sustained improvement in the signs and symptoms of Cushing's syndrome. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
|||
Condition ICMJE | Cushing's Syndrome | |||
Intervention ICMJE | Drug: mifepristone
Mifepristone 300 mg to 1200 mg once daily
Other Name: CORLUX
|
|||
Study Arms ICMJE | Experimental: Mifepristone
Mifepristone 300mg to 1200mg once daily
Intervention: Drug: mifepristone
|
|||
Publications * |
|
|||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE |
30 | |||
Original Estimated Enrollment ICMJE |
50 | |||
Actual Study Completion Date ICMJE | September 2012 | |||
Actual Primary Completion Date | September 2012 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
|||
Sex/Gender ICMJE |
|
|||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00936741 | |||
Other Study ID Numbers ICMJE | C-1073-415 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Current Responsible Party | Corcept Therapeutics | |||
Original Responsible Party | Coleman Gross, MD, Corcept Therapeutics | |||
Current Study Sponsor ICMJE | Corcept Therapeutics | |||
Original Study Sponsor ICMJE | Same as current | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
|
|||
PRS Account | Corcept Therapeutics | |||
Verification Date | February 2014 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |